Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly ...

A team of scientists is investigating a new type of antibody, which stimulates the immune system to target cancer cells an ...

This drug works by combining the antibody trastuzumab with a drug called emtansine. Trastuzumab works by binding to HER2 proteins that are found on the cells of HER2-positive breast cancer.

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim ...

Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer ...

Frazier Life Sciences has launched Callio Therapeutics with $187 million in series A funds and a HER2-targeted dual-payload ...

First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-⍺ (FR⍺) and ZW171, a ...

WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and ...

The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...

A new type of antibody which stimulates the immune system to target cancer cells slows tumour growth, according to new ...